Both Des(1-3)IGF-1 and IGF-1 LR3 emerged from the same general research need: an IGF-1 variant that resists rapid sequestration by IGF-binding proteins, making it more useful for sustained-exposure laboratory experiments than native IGF-1. Both target the N-terminal region of the IGF-1 molecule, since that is the region structural research identified as central to IGFBP recognition.
Where they differ is in how each achieves that goal — one by removal, the other by addition.
Des(1-3)IGF-1 removes the first three amino acids from the N-terminal end of native IGF-1's 70-amino-acid sequence — a smaller, more conservative structural change than the modification used to build IGF-1 LR3. The "Des" prefix is standard peptide-chemistry shorthand for "deleted," identifying exactly which residues are missing.
Published in-vitro research on Des(1-3)IGF-1 documents reduced IGFBP affinity alongside retained IGF-1 receptor activity, following the same general pattern seen with IGF-1 LR3, achieved through this different structural route.
IGF-1 LR3 takes the opposite structural approach: rather than removing residues, it adds a 13-amino-acid extension to the N-terminus, combined with an Arg3 substitution, bringing the total sequence to 83 amino acids. This larger structural modification produces a similarly reduced IGFBP affinity, via a mechanistically distinct route from Des(1-3)IGF-1's deletion strategy.
Both approaches leave the separate receptor-binding region of the IGF-1 molecule intact, which is why both retain IGF-1 receptor activity comparable to native IGF-1 in published binding studies.
Published literature does not treat one variant as categorically superior to the other. Researchers choosing between Des(1-3)IGF-1 and IGF-1 LR3 have generally been guided by experimental design considerations — such as which structural modification is least likely to interfere with a specific assay's other measurements, or simple availability from a given research-chemical source.
Both remain unregulated research chemicals, not approved pharmaceuticals, and both are treated purely as laboratory tools in the literature that documents them.
This article is comparative research information only. Neither Des(1-3)IGF-1 nor IGF-1 LR3 is part of REVIVE LAB UAE's catalog, and no dosing, administration, or protocol guidance is provided or implied for either compound.
Researchers with a genuine interest in either analog should consult primary peptide-chemistry and growth-factor literature directly.